QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.078220v1 312/3/1326    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Zhang, Y.-L. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Zhang, Y.-L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB LISINOPRIL

CARDIOVASCULAR

A New ATP-Sensitive Potassium Channel Opener Reduces Blood Pressure and Reverses Cardiovascular Remodeling in Experimental Hypertension

Department of Cardiovascular Pharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing, People's Republic of China (H.W., C.-L.L., Y.L.Z.); and the Thadweik Academy of Medicine, Beijing, People's Republic of China (C.-L.L.)

Some potassium channel openers (KCOs) are potent vasodilators that mainly target the ATP-sensitive potassium channels in vascular smooth muscle cells. Their lack of tissue selectivity limits their clinical use in hypertension therapy. Iptakalim [2,3-dimethyl-n-(1-methylethyl)-2-butylamine], which belongs to a novel chemical type of KCO, possesses unique pharmacological characteristics. In vitro experiments have shown that iptakalim could limit its vasorelaxing actions to resistance vessels. In this study, we investigate the antihypertensive effects of iptakalim on two different experimental hypertensive models: stroke-prone, spontaneously hypertensive rats (SHRsps) and two-kidney with one-clip renal hypertensive dogs (2K1C RHD). In acute hypotensive tests, iptakalim showed stable, long-lasting antihypertensive effects in SHRsps and 2K1C RHDs. Mean-while, it had little effect on heart rate when compared with pinacidil, nifedipine, captopril, or bisoprolol. In experimental therapeutic tests, repeated doses in SHRsps for 30 days or in 2K1C RHDs for 14 days produced consistent antihypertensive effects without causing tolerance. In separate experiments, chronic administration of iptakalim resulted in reversing hypertensive vascular remodeling in spontaneously hypertensive rats and hypertensive cardiac remodeling in SHRsps. These results suggest that iptakalim is a promising antihypertensive drug.

Address correspondence to: Hai Wang, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing, 100850, People's Republic of China. E-mail: wh9588{at}yahoo.com.cn

This article has been cited by other articles:

				N. Misaki, X. Mao, Y.-F. Lin, S. Suga, G.-H. Li, Q. Liu, Y. Chang, H. Wang, M. Wakui, and J. Wu Iptakalim, a Vascular ATP-Sensitive Potassium (KATP) Channel Opener, Closes Rat Pancreatic beta-Cell KATP Channels and Increases Insulin Release J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 871 - 878. [Abstract] [Full Text] [PDF]

				H. Wang, C. Long, Z. Duan, C. Shi, G. Jia, and Y. Zhang A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells Cardiovasc Res, February 1, 2007; 73(3): 497 - 503. [Abstract] [Full Text] [PDF]

				J. Wu, J. Hu, Y.-P. Chen, T. Takeo, S. Suga, J. DeChon, Q. Liu, K.-C. Yang, P. A. St. John, G. Hu, et al. Iptakalim Modulates ATP-Sensitive K+ Channels in Dopamine Neurons from Rat Substantia Nigra Pars Compacta J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 155 - 164. [Abstract] [Full Text] [PDF]

				H. Xue, Y.-L. Zhang, G.-S. Liu, and H. Wang A New ATP-Sensitive Potassium Channel Opener Protects the Kidney from Hypertensive Damage in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 501 - 509. [Abstract] [Full Text] [PDF]